MedTrace Logo

Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemic

NCT06109831 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 335

Last updated 2026-02-02

No results posted yet for this study

Summary

This is a Multicenter, Randomized, Double-Blind, Placebo-Parallel-Controlled, Phase II Clinical Stud to assess the reduction of low-density lipoprotein cholesterol (LDL-C) by SHR-1918 in patients with Hyperlipidemic.

Conditions

  • Hyperlipidemic

Interventions

DRUG

SHR-1918

SHR-1918

DRUG

SHR-1918 placebo

SHR-1918 placebo

Sponsors & Collaborators

  • Beijing Suncadia Pharmaceuticals Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-24
Primary Completion
2025-07-04
Completion
2025-07-04

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06109831 on ClinicalTrials.gov